Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have chronic plaque psoriasis based on a diagnosis for at least 6 months before baseline as determined by the investigator.~* Are a candidate for phototherapy and/or systemic therapy.~* Have both an Static Physician Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) score ≥12 at screening and at baseline.~* Have ≥10% body surface area (BSA) involvement at screening and baseline.~* If a male, agree to use a reliable method of birth control during the study.~* If female, agree to use highly effective method of contraception.~Exclusion Criteria:~* Predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis.~* Have a history of drug-induced psoriasis.~* Had a clinically significant flare of psoriasis during the 12 weeks before baseline.~* Use of tanning booths for at least 4 weeks before baseline.~* Concurrent or recent use of any biologic agent within the following periods prior to baseline: etanercept \<28 days; infliximab, adalimumab, certolizumab pegol, or alefacept \<60 days; golimumab \<90 days; rituximab \<12 months; secukinumab \<5 months; or any other biologic agent (e.g., ustekinumab) \<5 half lives.~* Have prior use of IL-23p19 antagonists (e.g., guselkumab, tildrakizumab, risankizumab), or have any condition or contraindication as addressed in the local labeling for guselkumab that would preclude the participant from participating in this protocol.~* Have previously completed or withdrawn from this study, participated in any other study with ixekizumab or guselkumab, have participated in any study investigating IL-23p19 antagonists, or have received treatment with ixekizumab.~* Have previously failed to respond to an IL-17 antagonist, per investigator assessment.~* Have had a live vaccination within 12 weeks of baseline.~* Have a known allergy or hypersensitivity to any biologic therapy.~* Have had any major surgery within 8 weeks of baseline.~* Have had a serious infection, have been hospitalized, or have received intravenous antibiotics for an infection within 12 weeks of baseline.~* Are women who are pregnant, or who are lactating (breast-feeding).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period.
- Guselkumab (Type: EXPERIMENTAL): During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).